We are live on ! Find out more
ELDN icon

Eledon Pharmaceuticals
ELDN

17 hedge funds and large institutions have $18.9M invested in Eledon Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

55% more funds holding

Funds holding: 11 → 17 (+6)

51% more capital invested

Capital invested by funds: $12.5M → $18.9M (+$6.39M)

0.2% less ownership

Funds ownership: 2.41% → 2.21% (-0.2%)

20% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 5

Holders
17
Holders Change
+6
Holders Change %
+54.55%
% of All Funds
0.39%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
4
Reduced
5
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BC
Boxer Capital
California
+$1.33M
2
RI
RTW Investments
New York
+$1.23M
3
Renaissance Technologies
Renaissance Technologies
New York
+$67.9K
4
PPA
Parametric Portfolio Associates
Washington
+$54.7K
5
DC
Derby & Company
Massachusetts
+$45.4K

Top Sellers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
-$5.01K
2
UBS Group
UBS Group
Switzerland
-$4.71K
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$3.24K
4
BlackRock
BlackRock
New York
-$1.33K
5
MAM
Meeder Asset Management
Ohio
-$1.33K
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$12.8M – – –
LSC
2
Lyon Street Capital
California
$1.71M – – –
BC
3
Boxer Capital
California
$1.64M +$1.33M +18,021 New
RI
4
RTW Investments
New York
$1.51M +$1.23M +16,667 New
Renaissance Technologies
5
Renaissance Technologies
New York
$554K +$67.9K +922 +18%
Vanguard Group
6
Vanguard Group
Pennsylvania
$212K +$1.77K +24 +1%
DC
7
Derby & Company
Massachusetts
$149K +$45.4K +617 +60%
BlackRock
8
BlackRock
New York
$80K -$1.33K -18 -2%
DS
9
DRW Securities
Illinois
$78K +$12.3K +167 +24%
D.E. Shaw & Co
10
D.E. Shaw & Co
New York
$72K -$3.24K -44 -5%
PPA
11
Parametric Portfolio Associates
Washington
$67K +$54.7K +743 New
Deutsche Bank
12
Deutsche Bank
Germany
$17K +$14.5K +197 New
UBS Group
13
UBS Group
Switzerland
$13K -$4.71K -64 -31%
MAM
14
Meeder Asset Management
Ohio
$4K -$1.33K -18 -30%
TRCT
15
Tower Research Capital (TRC)
New York
$1K -$5.01K -68 -81%
Barclays
16
Barclays
United Kingdom
– +$74 +1 New
Bank of America
17
Bank of America
North Carolina
– +$295 +4 New

ELDN Hedge Fund Activity: Q1 2018 in Review

17 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q1 2018, worth a combined $18.9M — up 51% from $12.5M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new ELDN positions and 0 closed out — a net gain of 6 holders — while 4 added to existing stakes and 5 trimmed.

The largest buyer was Boxer Capital, opening a new position worth an estimated $1.33M. The largest seller was Tower Research Capital (TRC), cutting an estimated $5.01K.

  • 17 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q1 2018, up from 11 in Q4 2017.
  • Funds reported $18.9M of Eledon Pharmaceuticals stock for Q1 2018, up 51% quarter-over-quarter.
  • 6 funds opened new Eledon Pharmaceuticals positions in Q1 2018 and 0 closed out, a net change of +6 holders.
  • The largest Eledon Pharmaceuticals buyer in Q1 2018 was Boxer Capital, an estimated $1.33M added.
  • The largest Eledon Pharmaceuticals seller in Q1 2018 was Tower Research Capital (TRC), an estimated $5.01K sold.

Based on aggregated 13F filings for Q1 2018.